Cargando…
Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity
[Image: see text] Naturally derived chemical compounds are the foundation of much of our pharmacopeia, especially in antiproliferative and anti-infective drug classes. Here, we report that a naturally derived molecule called carmaphycin B is a potent inhibitor against both the asexual and sexual blo...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2017
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554889/ https://www.ncbi.nlm.nih.gov/pubmed/28696697 http://dx.doi.org/10.1021/acs.jmedchem.7b00671 |
_version_ | 1783256855390191616 |
---|---|
author | LaMonte, Gregory M. Almaliti, Jehad Bibo-Verdugo, Betsaida Keller, Lena Zou, Bing Yu Yang, Jennifer Antonova-Koch, Yevgeniya Orjuela-Sanchez, Pamela Boyle, Colleen A. Vigil, Edgar Wang, Lawrence Goldgof, Gregory M. Gerwick, Lena O’Donoghue, Anthony J. Winzeler, Elizabeth A. Gerwick, William H. Ottilie, Sabine |
author_facet | LaMonte, Gregory M. Almaliti, Jehad Bibo-Verdugo, Betsaida Keller, Lena Zou, Bing Yu Yang, Jennifer Antonova-Koch, Yevgeniya Orjuela-Sanchez, Pamela Boyle, Colleen A. Vigil, Edgar Wang, Lawrence Goldgof, Gregory M. Gerwick, Lena O’Donoghue, Anthony J. Winzeler, Elizabeth A. Gerwick, William H. Ottilie, Sabine |
author_sort | LaMonte, Gregory M. |
collection | PubMed |
description | [Image: see text] Naturally derived chemical compounds are the foundation of much of our pharmacopeia, especially in antiproliferative and anti-infective drug classes. Here, we report that a naturally derived molecule called carmaphycin B is a potent inhibitor against both the asexual and sexual blood stages of malaria infection. Using a combination of in silico molecular docking and in vitro directed evolution in a well-characterized drug-sensitive yeast model, we determined that these compounds target the β5 subunit of the proteasome. These studies were validated using in vitro inhibition assays with proteasomes isolated from Plasmodium falciparum. As carmaphycin B is toxic to mammalian cells, we synthesized a series of chemical analogs that reduce host cell toxicity while maintaining blood-stage and gametocytocidal antimalarial activity and proteasome inhibition. This study describes a promising new class of antimalarial compound based on the carmaphycin B scaffold, as well as several chemical structural features that serve to enhance antimalarial specificity. |
format | Online Article Text |
id | pubmed-5554889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-55548892017-08-15 Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity LaMonte, Gregory M. Almaliti, Jehad Bibo-Verdugo, Betsaida Keller, Lena Zou, Bing Yu Yang, Jennifer Antonova-Koch, Yevgeniya Orjuela-Sanchez, Pamela Boyle, Colleen A. Vigil, Edgar Wang, Lawrence Goldgof, Gregory M. Gerwick, Lena O’Donoghue, Anthony J. Winzeler, Elizabeth A. Gerwick, William H. Ottilie, Sabine J Med Chem [Image: see text] Naturally derived chemical compounds are the foundation of much of our pharmacopeia, especially in antiproliferative and anti-infective drug classes. Here, we report that a naturally derived molecule called carmaphycin B is a potent inhibitor against both the asexual and sexual blood stages of malaria infection. Using a combination of in silico molecular docking and in vitro directed evolution in a well-characterized drug-sensitive yeast model, we determined that these compounds target the β5 subunit of the proteasome. These studies were validated using in vitro inhibition assays with proteasomes isolated from Plasmodium falciparum. As carmaphycin B is toxic to mammalian cells, we synthesized a series of chemical analogs that reduce host cell toxicity while maintaining blood-stage and gametocytocidal antimalarial activity and proteasome inhibition. This study describes a promising new class of antimalarial compound based on the carmaphycin B scaffold, as well as several chemical structural features that serve to enhance antimalarial specificity. American Chemical Society 2017-07-11 2017-08-10 /pmc/articles/PMC5554889/ /pubmed/28696697 http://dx.doi.org/10.1021/acs.jmedchem.7b00671 Text en Copyright © 2017 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. |
spellingShingle | LaMonte, Gregory M. Almaliti, Jehad Bibo-Verdugo, Betsaida Keller, Lena Zou, Bing Yu Yang, Jennifer Antonova-Koch, Yevgeniya Orjuela-Sanchez, Pamela Boyle, Colleen A. Vigil, Edgar Wang, Lawrence Goldgof, Gregory M. Gerwick, Lena O’Donoghue, Anthony J. Winzeler, Elizabeth A. Gerwick, William H. Ottilie, Sabine Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity |
title | Development of
a Potent Inhibitor of the Plasmodium Proteasome with
Reduced Mammalian Toxicity |
title_full | Development of
a Potent Inhibitor of the Plasmodium Proteasome with
Reduced Mammalian Toxicity |
title_fullStr | Development of
a Potent Inhibitor of the Plasmodium Proteasome with
Reduced Mammalian Toxicity |
title_full_unstemmed | Development of
a Potent Inhibitor of the Plasmodium Proteasome with
Reduced Mammalian Toxicity |
title_short | Development of
a Potent Inhibitor of the Plasmodium Proteasome with
Reduced Mammalian Toxicity |
title_sort | development of
a potent inhibitor of the plasmodium proteasome with
reduced mammalian toxicity |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554889/ https://www.ncbi.nlm.nih.gov/pubmed/28696697 http://dx.doi.org/10.1021/acs.jmedchem.7b00671 |
work_keys_str_mv | AT lamontegregorym developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT almalitijehad developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT biboverdugobetsaida developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT kellerlena developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT zoubingyu developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT yangjennifer developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT antonovakochyevgeniya developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT orjuelasanchezpamela developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT boylecolleena developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT vigiledgar developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT wanglawrence developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT goldgofgregorym developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT gerwicklena developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT odonoghueanthonyj developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT winzelerelizabetha developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT gerwickwilliamh developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity AT ottiliesabine developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity |